Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × NSCLC × aumolertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Pemetrexed 3 Carboplatin 3 HM781-36B 2 Gemcitabine 2 pembrolizumab 1 osimertinib 1 aumolertinib 1 aflutinib 1 Taxes 1 Paclitaxel 1 Erlotinib Hydrochloride 1 Clinical Trials, Phase I as Topic 1 Cisplatin 1 Bortezomib 1 BID protein, human 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated

8 enrolled 7 charts

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡